[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Inmed Pharmaceuticals Inc (INM)

Inmed Pharmaceuticals Inc (INM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

INM Stock Alert: What to Know as InMed, Mentari Announce Merger

InMed Pharmaceuticals (INM) shares ripped higher on May 19 as the company announced an all-stock merger with migraine drug developer Mentari Therapeutics. 

The combined company will trade on Nasdaq under a new ticker symbol, with INM shareholders expected to own about 1.51% of it once the transaction closes. 

Fundamentals

See More
  • Market Capitalization, $K 5,303
  • Shares Outstanding, K 3,314
  • Annual Sales, $ 4,940 K
  • Annual Income, $ -8,160 K
  • EBIT $ -8 M
  • EBITDA $ -7 M
  • 60-Month Beta 0.57
  • Price/Sales 0.46
  • Price/Cash Flow N/A
  • Price/Book 0.33

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6200 +174.19%
on 05/11/26
1.8000 -5.56%
on 05/19/26
+0.9769 (+135.10%)
since 04/20/26
3-Month
0.5750 +195.65%
on 03/31/26
1.8000 -5.56%
on 05/19/26
+0.8400 (+97.67%)
since 02/20/26
52-Week
0.5750 +195.65%
on 03/31/26
7.9800 -78.70%
on 06/02/25
-1.3492 (-44.25%)
since 05/20/25

Most Recent Stories

More News
INM Stock Alert: What to Know as InMed, Mentari Announce Merger

InMed stock rallied yesterday on a merger announcement with Mentari Therapeutics. Here’s why the transaction is concerning for INM investors.

INM : 1.6900 (+5.62%)
INM Stock Alert: Halper Sadeh LLC is Investigating Whether InMed Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior...

INM : 1.6900 (+5.62%)
InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies

Mentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapies

INM : 1.6900 (+5.62%)
InMed Pharmaceuticals Amends Preferred Investment Options

Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...

INM : 1.6900 (+5.62%)
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

Vancouver, British Columbia--(Newsfile Corp. - May 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...

INM : 1.6900 (+5.62%)
InMed Pharmaceuticals Amends Preferred Investment Options

Vancouver, British Columbia--(Newsfile Corp. - April 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...

INM : 1.6900 (+5.62%)
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying...

INM : 1.6900 (+5.62%)
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical TrialsConsistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimensional...

INM : 1.6900 (+5.62%)
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027Vancouver,...

INM : 1.6900 (+5.62%)
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

Vancouver, British Columbia--(Newsfile Corp. - March 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying...

INM : 1.6900 (+5.62%)

Business Summary

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It engages in developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol in diseases with unmet medical need. InMed Pharmaceuticals Inc. is based in VANCOUVER, BC.

See More

Key Turning Points

3rd Resistance Point 2.3200
2nd Resistance Point 2.0600
1st Resistance Point 1.8300
Last Price 1.6900
1st Support Level 1.3400
2nd Support Level 1.0800
3rd Support Level 0.8500

See More

52-Week High 7.9800
Fibonacci 61.8% 5.1513
Fibonacci 50% 4.2775
Fibonacci 38.2% 3.4037
Last Price 1.6900
52-Week Low 0.5750

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.